Mangosteen Extract Attenuates the Metabolic Disorders of High-Fat-Fed Mice by Activating AMPK

Journal of Medicinal Food

Volumn 19, Issue 2, 2016, Pages 148-154

  Chae, Hee Sung ^a   Kim, Young Mi ^a   Bae, Jin Kyung ^a   Sorchhann, Sochivak ^a   Yim, Sreymom ^a   Han, Ling ^a   Paik, Jin Hyub ^b   Choi, Young Hee ^a   Chin, Young Won ^a  

^a Dongguk University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

AMP activated protein kinase; antiobesity; Garcinia mangostana; Sirtuin 1

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ALANINE AMINOTRANSFERASE; ANTIOBESITY AGENT; ASPARTATE AMINOTRANSFERASE; FATTY ACID; GARCINIA MANGOSTANA EXTRACT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIRTUIN 1; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; PLANT EXTRACT;

ADIPOGENESIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVATION; FATTY ACID BLOOD LEVEL; GARCINIA MANGOSTANA; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENERGY METABOLISM; LIPID DIET; LIVER; METABOLIC DISEASES; METABOLISM;

ADIPOGENESIS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-OBESITY AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET, HIGH-FAT; ENERGY METABOLISM; GARCINIA MANGOSTANA; LIVER; MALE; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; SIRTUIN 1; TRIGLYCERIDES;

EID: 84958043332     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3496     Document Type: Article

References (34)

1. Nawrocki AR, Scherer PE: Keynote review: The adipocyte as a drug discovery target. Drug Discov Today 2005;10:1219-1230.
2. Gregoire FM: Adipocyte differentiation: From fibroblast to endocrine cell. Exp Biol Med 2001;226:997-1002.
3. Hsieh YH, Wang SY: Lucidone from Lindera erythrocarpa Makino fruits suppresses adipogenesis in 3T3-L1 cells and attenuates obesity and consequent metabolic disorders in high-fat diet C57BL/6 mice. Phytomedicine 2013;20:394-400.
4. Lee EJ, Kang M, Kim YS: Platycodin D inhibits lipogenesis through AMPKa-PPARc2 in 3T3-L1 cells and modulates fat accumulation in obese mice. Planta Med 2012;78:1536-1542.
5. Ruderman NB, Xu XJ, Nelson L, et al.: AMPK and SIRT1: A long-standing partnership? Am J Physiol Endocrinol Metab 2010; 298:E751-E760.
6. Chin YW, Kinghorn AD: Structural characterization, biological effects, and synthetic studies on xanthones from mangosteen (Garcinia mangostana), a popular botanical dietary supplement. Mini Rev Org Chem 2008;5:355-364.
7. Devi Sampath P, Vijayaraghavan K: Cardioprotective effect of alpha-mangostin, a xanthone derivative from mangosteen on tissue defense system against isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol 2007;21:336-339.
8. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD: Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod 2008; 71:1161-1166.
9. Sakagami Y, Iinuma M, Piyasena KG, Dharmaratne HR: Antibacterial activity of alpha-mangostin against vancomycin resistant Enterococci (VRE) and synergism with antibiotics. Phytomedicine 2005;12:203-208.
10. Shen Q, Chitchumroonchokchai C, Thomas JL, et al.: Adipocyte reporter assays: Application for identification of anti-inflammatory and antioxidant properties of mangosteen xanthones. Mol Nutr Food Res 2014;58:239-247.
11. Quan X, Wang Y, Ma X, et al.: a-Mangostin induces apoptosis and suppresses differentiation of 3T3-L1 cells via inhibiting fatty acid synthase. PLoS One 2012;7:e33376.
12. Stern JS, Peerson J, Mishra AT, Mathukumalli VS, Konda PR: Efficacy and tolerability of an herbal formulation for weight management. J Med Food 2013; 16:529-537.
13. Choi YH, Han SY, Kim YJ, Kim YM, Chin YW: Absorption, tissue distribution, tissue metabolism and safety of a-mangostin in mangosteen extract using mouse models. Food Chem Toxicol 2014;66:140-146.
14. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG: Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alphadependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009;49:1913-1925.
15. Black PH: The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003;17:350-364.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr., Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735-2752.
17. Choi SS, Diehl AM: Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008;19:295-300.
18. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110.
19. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
20. Carling D: The AMP-activated protein kinase cascade-A unifying system for energy control. Trends Biochem Sci 2004;29:18-24.
21. Bijland S, Mancini SJ, Salt IP: Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci 2013;124:491-507.
22. Uto-Kondo H, Ohmori R, Kiyose C, Kishimoto Y, Saito H, Igarashi O, Kondo K: Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J Nutr 2009;139:51-57.
23. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
24. Chandra V, Huang P, Hamuro Y, et al.: Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature 2008;456:350-356.
25. Handschin C, Spiegelman BM: Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006;27:728-735.
26. Jäger S, Handschin C, St-Pierre J, Spiegelman BM: AMPactivated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1a. Proc Natl Acad Sci 2007;104: 12017-12022.
27. Cantó C, Auwerx J: Targeting sirtuin 1 to improve metabolism: All you need is NAD(+)? Pharmacol Rev 2012;64:166-187.
28. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P: Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 2008;582:46-53.
29. Iwabu M, Yamauchi T, Okada-Iwabu M, et al.: Adiponectin and AdipoR1 regulate PGC-1a and mitochondria by Ca2+ and AMPK/SIRT1. Nature 2010;464:1313-1319.
30. Picard F, Kurtev M, Chung N, et al.: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-776.
31. Qiang L, Wang L, Kon N, et al.: Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of PPARc. Cell 2012;150:620-632.
32. Jin Q, Zhang F, Yan T, Liu Z, Wang C, Ge X, Zhai Q: C/EBPa regulates SIRT1 expression during adipogenesis. Cell Res 2010;20:470-479.
33. MacDougald OA, Mandrup S: Adipogenesis: Forces that tip the scales. Trends Endocrinol Metab 2002;13:5-11.
34. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD: Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001;50:123-130.